Completed NA INTERVENTIONAL NCT00002043

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

Sponsor: Jacobus Pharmaceutical

Conditions HIV Infections Pneumonia, Pneumocystis Carinii

Interventions Dapsone

Updated 6 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates HIV Infections and Pneumonia, Pneumocystis Carinii and is currently completed. Jacobus Pharmaceutical leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed NA
Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jacobus Pharmaceutical

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States